کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
7625735 | 1494575 | 2018 | 34 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
In-vitro metabolism, CYP profiling and metabolite identification of E- and Z- guggulsterone, a potent hypolipidmic agent
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
HLMGuggulsteroneCYP450MBSNADPHIC501-aminobenzotriazole - 1-آمینوبنزوتریازولDMSO - DMSOLC–MS/MS - LC-MS / MSinternal standard - استاندارد داخلیMetabolic stability - ثبات متابولیکDimethylsulfoxide - دیمتیل سولفواکسیدCytochrome P450 - سیتوکروم پی۴۵۰Liquid chromatography-tandem mass spectrometry - طیف سنجی جرمی کروماتوگرافی مایع دو طرفهInhibitory Concentration 50% - غلظت مهاری 50٪reduced form of nicotinamide adenine dinucleotide phosphate - فرم کاهش یافته ای از نیکوتین آمید آدنین دینکلوتید فسفاتCYP inhibition - مهار CYPHuman Liver Microsomes - میکروسومهای کبدی انسانیhigh-performance liquid chromatography - کروماتوگرافی مایعی کاراHPLC - کروماتوگرافی مایعی کارا
موضوعات مرتبط
مهندسی و علوم پایه
شیمی
شیمی آنالیزی یا شیمی تجزیه
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The polyphenol E- and Z-gugggulsterone (GS) is an antagonist ligand for the Farnesoid X Receptor (FXR) and known to possess potent hypolipidemic properties as shown in various preclinical and clinical studies. In the present study, we examined drug-like properties of GS by assessing the isomers plasma protein binding, metabolic stability, CYP profiling, CYP inhibition, and phase I and II metabolite identification of GS using liver microsomes and S9 fractions. GS followed Lipinski and Veber rules and were substrates of CYP3A CYP2C19 and CYP2D6 isoforms. GS was also found to be an inhibitor of CYP2C19 with an IC50 value of 2.1â¯Î¼M. GS showed high plasma protein binding (<96%), and low to moderate binding with human serum albumin (â¼70%). Unbound intrinsic clearances (CLint, in-vitro) was determined to be low at 0.029â¯Â±â¯0.0009 and 0.027â¯Â±â¯0.008â¯mL/min/mg protein for E- and Z-isomer, respectively in human liver microsomes. Nineteen phase I and II metabolites were identified and hydroxylation was found to be major metabolic pathway using human liver microsomes and S9 fractions. The results of in-vitro drug-metabolism studies provide impetus for further structural modification of this pharmacophore in order to improve the stability of drugs with potent hypolipidemic effects.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Pharmaceutical and Biomedical Analysis - Volume 160, 25 October 2018, Pages 202-211
Journal: Journal of Pharmaceutical and Biomedical Analysis - Volume 160, 25 October 2018, Pages 202-211
نویسندگان
Yashpal S. Chhonker, Hardik Chandasana, Veenu Bala, Rao Mukkavilli, Deepak Kumar, Subrahmanyam Vangala, Rabi S. Bhatta,